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and Christopher KT Farmer1*Abstract
Background: The significant impact Acute Kidney Injury (AKI) has on patient morbidity and mortality emphasizes
the need for early recognition and effective treatment. AKI presenting to or occurring during hospitalisation has been
widely studied but little is known about the incidence and outcomes of patients experiencing acute elevations in
serum creatinine in the primary care setting where people are not subsequently admitted to hospital. The aim of this
study was to define this incidence and explore its impact on mortality.
Methods: The study cohort was identified by using hospital data bases over a six month period.
Inclusion criteria: People with a serum creatinine request during the study period, 18 or over and not on renal
replacement therapy.
The patients were stratified by a rise in serum creatinine corresponding to the Acute Kidney Injury Network (AKIN)
criteria for comparison purposes. Descriptive and survival data were then analysed.
Ethical approval was granted from National Research Ethics Service (NRES) Committee South East Coast and from the
National Information Governance Board.
Results: The total study population was 61,432. 57,300 subjects with ‘no AKI’, mean age 64.The number (mean age) of
acute serum creatinine rises overall were, ‘AKI 1’ 3,798 (72), ‘AKI 2’ 232 (73), and ‘AKI 3’ 102 (68) which equates to an
overall incidence of 14,192 pmp/year (adult). Unadjusted 30 day survival was 99.9% in subjects with ‘no AKI’, compared
to 98.6%, 90.1% and 82.3% in those with ‘AKI 1’, ‘AKI 2’ and ‘AKI 3’ respectively. After multivariable analysis adjusting for
age, gender, baseline kidney function and co-morbidity the odds ratio of 30 day mortality was 5.3 (95% CI 3.6, 7.7), 36.8
(95% CI 21.6, 62.7) and 123 (95% CI 64.8, 235) respectively, compared to those without acute serum creatinine rises as
defined.
Conclusions: People who develop acute elevations of serum creatinine in primary care without being admitted to
hospital have significantly worse outcomes than those with stable kidney function.
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The prevalence of AKI is increasing [1,2] associated with
an aging population, the increase in comorbidities includ-
ing obesity, diabetes and hypertension in the developed
world and advances in medical practice including aggres-
sive investigative procedures, invasive clinical procedures
and increased sepsis [3,4]. AKI is a complex disorder with
multiple aetiologies and risk factors and may often be* Correspondence: Chris.Farmer1@nhs.net
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unless otherwise stated.preventable and reversible. Clinically, its manifestations
may range from a small isolated elevation in serum cre-
atinine (SCr) to loss of urine output, advanced kidney
failure, hyperkalaemia, disturbed whole body acid–base
balance manifest as acidosis and fluid overload [4-12].
There is now evidence that even small isolated increases
in serum creatinine have an associated increase in short-
term morbidity and mortality, in longer-term outcomes
including one year mortality [5,13] and even more so
when renal replacement therapy is required [1,14-16].
The risk of AKI and the significant impact it has on
patient morbidity and mortality emphasizes the need forThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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highlighted in published clinical guidance [17] and the
2009 National Confidential Enquiry into Patient Out-
come and Death in the setting of AKI in hospital, which
uncovered systematic failings in the identification and
subsequent management [2].
Although AKI presenting to or occurring during hos-
pitalisation has been widely studied and reported in the
literature, however all that data relates to in-patient stud-
ies. Little is known about the incidence and outcomes of
patients experiencing acute elevations in SCr in primary
care who are not subsequently admitted to hospital.
The hypothesis for the study was that acute elevations in
SCr measured in the community may represent episodes of
AKI and therefore will be associated with increased mortal-
ity in the community compared to those who did not have
acute elevations in the serum creatinine. The aim of this
study was to describe the incidence in the community of
acute elevations in SCr defined using the Acute Kidney
Injury Network (AKIN) criteria and the associated mortal-
ity in patients who had not been subsequently admitted to
hospital. We aligned these acute changes to the AKIN
criteria in order to compare outcomes with the published
literature.
Methods
This was an observational database study using data
from two databases to collate the study cohort;
 The pathology database: East Kent is served by 3
acute hospitals with a single laboratory service
feeding into a regional pathology database which
holds all records of blood tests requested from GPs,
outpatients and inpatients
 The hospital data warehouse: This contains data
from coded episodes on all admissions and
outpatient activity in East Kent.
Ethical approval was granted by the National Research
Ethics Service (NRES) Committee South East Coast.
National Information Governance Board (NIGB) approval
was given to link the data on these databases.
The study cohort was recruited between 1st of February
2009 – 31st July 2009 from the East Kent population in
the United Kingdom, numbering approximately 744,400
people of whom 582,300 were over the age of 18. This
cohort was followed up either until the primary endpoint
(death) or for a period of two years. All patients with a
SCr request from the community, with a valid NHS num-
ber and aged 18 or over during the recruitment period
were identified using the pathology database. The data
was then linked to the hospital information system and
pathology databases using the NHS number to ascertain
outcomes and co-morbidity data. Patients were excludedfrom the data set if they had a non-elective admission to
hospital during either the recruitment period or the follow
up period, if they did not have a baseline SCr within
12 months of the incident SCr or that they were already
on renal replacement therapy. The data was then pseudo-
nymised in accordance with the NHS information govern-
ance standards to protect patient confidentiality [18].
There were 135,052 patients with both unique NHS
number and a SCr request from primary care identified
between 1st of February 2009 and 31st July 2009, the
study recruitment period; 24,019 people were then
excluded because they were either under the age of 18,
or they had an emergency admission during either the
study recruitment period they were already on RRT, or
the 24 months follow up period. The remaining 111,033
patients were identified using the NHS number on the
hospital data warehouse to ascertain date of death and
co-morbidity. Of these, 61,443 had a valid SCr that could
be used as a baseline. A further 11 patients had to be
removed as the data could not be validated, leaving the
study population as 61,432. This process is shown in a
data flow diagram (Figure 1). The patient cohort was
then split into two study groups; people with and with-
out acute elevations in SCr. Those with acute elevations
were then defined and stratified according to the Acute
Kidney Injury Network SCr criteria [19]. People who
had emergency (non-elective admissions) during the
study period were excluded and formed a cohort for a
separate study [20].
The AKIN criteria require a baseline SCr within
48 hours of the index value, however in primary care
blood tests are seldom repeated this frequently, for that
reason the lowest SCr in the twelve months prior to the
index value was used as the baseline. This method has
been previously described by LaFrance and Miller [21]. If
an individual with a raised SCr had multiple blood tests
during the study recruitment period the highest SCr was
used. In those people not fulfilling AKIN criteria the date
of the first SCr in the recruitment period was used as the
incident creatinine for subsequent follow up. For des-
criptive purposes those not fulfilling AKIN criteria were
referred to as “no AKI”, and those fulfilling AKIN criteria
as “AKI 1”, “AKI 2” and “AKI 3” (Table 1).
Charlson co-morbidity scores were used to measure
disease burden and was calculated according to the
method developed by the Dr Foster Unit, published by
Bottle and Aylin [22].
Serum creatinine was measured using an enzymatic
method on Abbott Architect analysers (Abbott Diagnostics,
Maidenhead, Berkshire, UK). The enzymatic method
for creatinine is standardized against NIST SRM 967
and thus is traceable to isotope dilution mass spectrom-
etry (ID-MS). The assay was related to an ID-MS assay
according to the equation: Abbott enzymatic = 0.982
Figure 1 Derivation of the study population. This diagram shows
the derivation of the study population with the numbers of patients
remaining at each level exclusion criteria.
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creatinine plus enzymatic assay (Hoffman-La Roche,
Basel, Switzerland) used to re-express the MDRD equa-
tion according to the equation: Abbott enzymatic = 1.0338
(Roche enzymatic) + 0.98, unpublished data, E.J. Lamb). In
order to establish baseline kidney function in all patients
Glomerular Filtration Rate (GFR) was calculated using the
Modified Diet in Renal Disease (MDRD) formula [23].
The association between acute elevations in SCr cate-
gorised by AKIN criteria and survival was examined.
The primary outcome assessed was all cause mortality.
The results were expressed as Kaplan-Meier survival
curves, first unadjusted and then adjusted for age, gender,
stage of Chronic Kidney Disease (CKD) and Charlson
co-morbidity score. Cox regression survival analysis wasTable 1 Definitions for the stage of AKI: using the AKI networ
Stage Serum creatinine criteria
Stage 1 1.5 – 1.9 times baseline cre
Stage 2 2.0 – 2.9 times baseline cre
Stage 3 3.0 times the baseline OR In
This table shows the Acute Kidney Injury Network serum creatinine criteria, which w
criteria has been referred to as AKI 1a in this paper. **AKI defined only using thesethen used to examine the temporal relationship between
the incident creatinine and death. These results were
expressed as hazard ratios.
Finally the probability of dying at 30 days and12 months
was estimated using logistic regression analysis. To allow
for possible confounding variables, a series of four models
were fitted with varying adjustments for other variables to
allow comparison between the categories
The models fitted were as follows:
1. Unadjusted relationship between elevated serum
creatinine defined by AKIN criteria and death
2. The relationship between elevated serum creatinine
defined by AKIN criteria and death, adjusted for age
and sex only
3. The relationship between elevated serum creatinine
defined by AKIN criteria and death, adjusted for
age, sex, baseline CKD stage & using individual
co-morbidities
4. The relationship between elevated serum creatinine
defined by AKIN criteria and death,, for age, sex,
baseline CKD stage & Charlson score
There was a non-linear relationship between age and
all outcomes, therefore a linear and squared term were
included for age to best fit the observed relationships.
Around 22% of patients had missing comorbidity data,
and thus potentially excluded from models 3 and 4. In
order to retain these patients in the analysis, an additional
'missing' category was included for the Charlson score in
model 4. Each of the individual comorbidities was missing
for the same patients, and thus it was not possible to
include an additional category for each of these. Instead it
was assumed that the individual comorbidities were
absent for those with missing data, and an additional vari-
able, missing comorbidity or not, was included in the
model. Since none of the patients with AIDS died within
30 days of the incident creatinine AIDS was omitted from
the analysis of 30-day mortality.
The data was then re-analysed dividing patient s into 6
groups based on their AKI status, no AKI, AKIN1,
AKIN1a, AKIN2, AKIN3 and AKIN3a. The aim of the
all analyses was to compare between the six AKI groups.
An additional variable was added to the model three and
four to adjust for time between incident creatinine and
baseline creatinine (models 5, 6, 7 & 8).k criteria
atinine OR an increase in serum creatinine of > 0.3 mg/dl (>26.5mmols/l*)
atinine 0.5 ml/kg/h for X12 hours
crease in serum creatinine to >4.0 mg /dl (353.6 mmols/l**)
as used to stratify the primary care cohort. *AKI defined only using these
criteria had been referred to as AKI 3a.19
Table 2 Patient characteristics for all patients studied
Variable All (n = 61,432) No AKI (n = 57,300) AKI 1 (n = 3,798) AKI 2 (n = 232) AKI 3 (n = 102) P-value(*)
Age in years mean (SD) 64.1 (15.8) 64.1 (15.8) 72.2 (14.4) 72.9 (13.3) 67.7 (15.4) <0.001
−39 (%) 7.8 8.4 4.0 2.2 7.8 <0.001
40-59 (%) 24.9 26.4 12.4 12.5 17.7
60-79 (%) 49.4 49.4 51.3 51.3 50.0
80 + (%) 17.9 15.8 32.4 34.1 24.5
Female (%) 55.1 55.7 46.2 58.6 43.1 <0.001
Baseline GFR
>60 (%) 77.4 79.2 52.0 71.1 51.0 <0.001
45 - <60 (%) 15.4 15.0 20.8 18.1 7.8
30 - <45 (%) 5.6 4.8 17.1 7.8 6.9
<30 (%) 1.6 1.0 10.1 3.0 34.3
This table shows age at incident creatinine, gender and baseline GFR. (*)All comparisons performed using the Chi-square test, except for age on a continuous
scale, where analysis of variance (ANOVA) was used.
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There were 61,432 people were included in the study
cohort. The mean ages of people with no AKI, AKI 1,
AKI 2 and AKI 3 were 64.1 years, 72.2 years, 72.9 years
and 67.7 years respectively. The gender split showsTable 3 Prevalence of comorbidities in the study cohort
Variable Total (47,716) No AKI (n = 43,960) AKI
Co - morbidity
AIDS (%) 0.1 0.1 0.1
Malignancy** (%) 6.7 6.0 14.2
CHF (%(%) 3.0 2.2 11.8
COPD (%) 9.1 8.6 15.2
Stroke/TIA (%) 4.3 3.9 9.0
Dementia (%) 0.8 0.7 2.1
Diabetes (%) 11.8 10.9 22.3
Hemiplegia (%) 1.0 1.0 1.5
Hypertension (%) 28.0 26.2 48.6
MI (%) 4.1 3.7 8.5
Solid tumour** (%) 1.1 0.9 2.5
Liver disease (%) 1.0 0.9 2.1
PVD (%) 2.3 1.9 7.0
Peptic ulcer (%) 0.6 0.5 1.5
CKD (%) 3.1 1.9 16.9
Rheumatic dis. (%) 3.4 3.1 6.6
Charlson score:
≤0 64.3 66.9 34.1
1-10 23.5 22.8 31.2
11+ 12.3 10.3 34.7
(*)P-values comparing difference between four AKI categories.
(**)These two variables are mutually exclusive because ‘Solid tumour’ may contain
This table shows the proportions of comorbidities for people who had comorbidity rec
Chronic Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), Myocardiafemales as slightly under represented in AKI 1 and AKI
3 and slightly over represented in groups “no AKI” and
AKI 2.
Approximately 7% (4,132/61,432) of people had an





















orded (n = 47,716). All comparisons performed using the Chi-square test.
l Infarction (MI), Peripheral Vascular Disease (PVD), Chronic Kidney Disease (CKD).
Table 4 A summary of the survival estimates
Variable No AKI AKIN 1 AKIN 2 AKIN 3
Number of patients 57,300 3,798 232 102
Number of deaths 2,582 630 61 28
% of deaths 4.5 16.6 26.3 27.5
1 m survival (95% CI) 0.999 (0.999, 0.999) 0.987 (0.983, 0.990) 0.925 (0.882, 0.953) 0.840 (0.752, 0.899)
6 m survival (95% CI) 0.992 (0.991, 0.992) 0.961 (0.954, 0.967) 0.872 (0.967, 0.970) 0.800 (0.707, 0.866)
12 m survival (95% CI) 0.980 (0.979, 0.981) 0.918 (0.909, 0.926) 0.827 (0.772, 0.871) 0.760 (0.664, 0.824)
18 m survival (95% CI) 0.969 (0.967, 0.970) 0.880 (0.869, 0.890) 0.801 (0.743, 0.847) 0.750 (0.653, 0.824)
24 m survival (95% CI) 0.955 (0.953, 0.957) 0.835 (0.823, 0.846) 0.757 (0.695, 0.807) 0.740 (0.642, 0.815)
This table shows the survival estimates for the 2 year follow up period along with corresponding confidence intervals in 6 monthly intervals.
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AKI 2 (232), AKI 3 (102) (Table 2).
We subsequently analysed the data using both MDRD
and CKD–EPI estimating equations, we only present the
results using MDRD as the frequency distribution using
CKD-EPI was similar and the former is the more com-
monly used. People with a GFR of less than 60 were
more likely to have an episode of AKI. In patients with
stage 4 or 5 CKD only 7% of patients with AKI 1 and 3%
of AKI 3 were defined using a relative change in creatinine.
Despite the likelihood of inherent variability in SCr esti-
mation contributing to elevations in SCr in those with
more advanced CKD only 10% of those with AKI 1 had
stage 4 and 5 CKD (Table 2).
Co-morbidity data were available in 78% of the study
cohort. Patients fulfilling AKIN criteria had more co-
morbidity than those who did not. In general this was as-
sociated with increasing elevation in SCr shown in Table 3.
The association between SCr elevation and Charlson co-
morbidity score was examined as a categorical variable.
The proportion of patients with a Charlson co-morbidityFigure 2 Unadjusted Kaplan-Meier survival curves by AKIN
criteria. This figure shows the survival curves by AKIN criteria up to
24 months post incident serum creatinine using unadjusted data.
All patients (n = 61,432). The majority of the effect is seen in the first
30 days.score of ≤0 fell with increasing SCr elevation, from 67% of
patients with “no AKI” to 22% with AKI 3 (Table 3).
There was a total of 3,301 deaths from 61,432 patients,
2582 (4.5%) with ‘No AKI’, 630 (16.6%), AKI 1 61 (26.3%)
AKI 2 and 28 (27.5%) AKI 3. Survival analysis using un-
adjusted data demonstrated that those who fulfilled
AKIN criteria did worse than those who did not with
98% of patients still alive at 12 months compared with
92% AKI 1, 83% AKI 2, and 76% AKI 3 (Table 4). The
majority of this effect was seen in the first thirty days
and the probability of survival at 30 days fell 99% in AKI
1 to 84% in AKI 3 (Figure 2).
This effect was still apparent when adjusted for age
gender, co-morbidity and baseline GFR (Figure 3).
Cox regression analysis shows that the increased risk of
death at 24 months as, 1.81 (1.65, 1.99), 2.76 (2.11, 3.62),
2.76 (2.11, 3.62) respectively compared to the reference
range (p < 0.001). This suggests a temporal relationship
between acute elevation in SCr and mortality (Table 5).
Logistic regression analysis for all-cause mortality at
30 days suggested a highly significant difference between
AKI groups in all models, showing that patients with a
higher stage of AKI had an increased likelihood of death.Figure 3 Adjusted Kaplan-Meier survival curves by AKIN criteria.
This figure shows the survival curves by AKIN criteria up to 24 months.
Adjusted for age at incident creatinine, gender, baseline GFR and
Charlson score. Patients with co-morbidity data (n = 47,716).
Table 5 This table shows Logistic regression analysis for
30 day survival
Model Variable Odds ratio (95% CI) P-value
1 -No AKI 1 <0.001
-AKIN 1 11.4 (7.98, 16.3)
-AKIN 2 88.7 (54.4, 145)
-AKIN 3 173 (98.7, 302)
2 -No AKI 1 <0.001
-AKIN 1 6.74 (4.67, 9.72)
-AKIN 2 58.9 (35.4, 98.0)
-AKIN 3 158 (87.0, 288)
Female sex 0.69 (0.50, 0.95) <0.001
Age (*) -Linear term 0.61 (0.22, 1.67) <0.001
-Squared term 1.09 (1.02, 1.18)
3 -No AKI 1 <0.001
-AKIN 1 5.42 (3.67, 8.00)
-AKIN 2 39.8 (22.8, 69.6)
-AKIN 3 185 (94.0, 365)
Female sex 0.67 (0.48, 0.94) 0.02
Age (*) -Linear term 0.39 (0.14, 1.10) <0.001
-Squared term 1.13 (1.06, 1.22)
Any malignancy 3.68 (2.36, 5.74) <0.001
CHF 2.16 (1.29, 3.65) 0.004
CPD 1.00 (0.59, 1.69) 1.00
Cerebrovascular disease 0.54 (0.27, 1.08) 0.08
Dementia 4.87 (2.50, 9.47) <0.001
Diabetes 1.21 (0.77, 1.89) 0.42
Hemiplegia or paraplegia 2.94 (0.96, 9.01) 0.06
Hypertension 1.14 (0.79, 1.66) 0.48
MI 0.82 (0.41, 1.64) 0.57
Solid tumour 7.55 (4.20, 13.6) <0.001
Mild liver disease 2.28 (0.83, 6.32) 0.11
PVD 1.21 (0.60, 2.43) 0.60
Peptic ulcer 2.89 (1.05, 7.98) 0.04
Renal disease 0.46 (0.23, 0.91) 0.03
Rheumatic disease 0.56 (0.19, 1.59) 0.28
Missing data 1.52 (0.87, 2.67) 0.14
GFR > 60 1 0.78
GFR 45 - < 60 0.82 (0.53, 1.26)
GFR 30 - < 45 0.83 (0.49, 1.42)
GFR < 30 0.85 (0.38, 1.89)
4 -No AKI 1 <0.001
-AKIN 1 5.26 (3.57, 7.74)
-AKIN 2 36.8 (21.6, 62.7)
-AKIN 3 123 (64.8, 235)
Table 5 This table shows Logistic regression analysis for
30 day survival (Continued)
Female sex 0.74 (0.53, 1.02) 0.07
Age (*) -Linear term 0.52 (0.19, 1.42) <0.001
-Squared term 1.10 (1.03, 1.18)
Charlson -≤0 1 <0.001
-1-10 2.67 (1.59, 4.49)
-11+ 5.24 (3.25, 8.44)
-No info 2.05 (1.11, 3.79)
GFR > 60 1 0.03
GFR 45 - < 60 0.65 (0.43, 1.00)
GFR 30 - < 45 0.63 (0.38, 1.06)
GFR < 30 0.42 (0.20, 0.92)
(*)Odds Ratio reported for a 10-year increase in age.
This table shows the logistic regression analysis for the like-hood of dying in
the first 30 days following an acute elevation in serum creatinine. Model 2
adjusts for age and gender, model 3 also adjusts for individual co-morbidity
and model 4 replaces co-morbidity with a Charlson score to measure the
effect of cumulative co-morbidity burden.
Chronic Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD),
Myocardial Infarction (MI), Peripheral Vascular Disease (PVD), Chronic Kidney
Disease (CKD).
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death in AKI 1 patients increased by 11.4 times that of
patients with no AKI, increasing to a 180 time more
likely for patients with AKI 3. The impact AKI had on
likelihood of death was attenuated after adjusting for
some confounding variables. When adjusting for disease
burden in model 4, death in the first 30 days was, 5.26,
36.8 and 123 times more likely compared to those with
‘No AKI’ (Table 6).
Similar analyses were performed at 12 months (data
not shown). This showed a similar but less marked effect
with increasing follow up.
However the size of the effect was altered when
accounting for differences between those who were
defined using an absolute or relative change in AKI 1
and 3 (Figure 4).
Those defined by an absolute change having better
survival than those defined by a relative change in serum
creatinine. Cox survival analysis at 30 days showed AKI
1a 0.991 (0.983, 0.99) AKI 1 0.979 (0.969, 0.986), AKI 2
0.925 (0.882, 0.953), AKI 3a 0.971 (0.809, 0.996), AKI 3
0.773 (0.652, 0.856)
Logistic regression analysis for all-cause mortality sug-
gested a highly significant association between AKI
groups and death within 30 days, with the general trend
being that a higher AKI stage was associated with an in-
creased risk of an early death. After adjusting for the in-
dividual comorbidities (model 7), the odds of 30 day
mortality for AKI 1a patients was 4 times greater than
for patients with no AKI, and 10 times time for AKI 1
patients. The odds were over 40 times greater for AKI 2
Table 6 This table shows logistic regression analysis at
30 days with AKI defined by absolute change as separate
groups
Model Variable Odds Ratio (95% CI) P-value
5 No AKI 1 <0.001
-AKI 1 18.8 (12.0, 29.7)
-AKI 1a 8.26 (54.4, 12.9)
-AKI 2 88.7 (98.7, 145)
-AKI 3 269 (148, 488)
-AKI 3a 24.4 (3.30, 181)
6 No AKI 1 <0.001
-AKI 1 14.0 (8.84, 22.2)
-AKI 1a 4.42 (2.81, 6.97)
-AKI 2 59.4 (35.7, 98.8)
-AKI 3 233 (121, 447)
-AKI 3a 25.6 (3.33, 197)
Female sex 0.61 (0.44, 0.85) <0.001
Age(*) -Linear term 0.61 (0.22, 1.68) <0.001
-Squared term 1.09 (1.02, 1.17)
7 No AKI 1 <0.001
-AKI 1 9.69 (5.91, 15.9)
-AKI 1a 3.99 (2.46, 6.49)
-AKI 2 42.9 (24.5, 75.1)
-AKI 3 237 (115, 490)
-AKI 3a 44.5 (4.83, 409)
Female sex 0.62 (0.44, 0.88) 0.007
Age(*) -Linear term 0.39 (0.14, 1.10) <0.001
-Squared term 1.13 (1.06, 1.22)
Any malignancy 3.62 (2.31, 5.67) <0.001
CHF 2.32 (1.36, 3.94) 0.002
CPD 1.07 (0.63, 1.82) 0.81
Cerebrovascular disease 0.48 (0.23, 0.98) 0.05
Dementia 4.88 (2.48, 9.60) <0.001
Diabetes 1.19 (0.75, 1.89) 0.45
Hemiplegia or paraplegia 2.87 (0.91, 9.09) 0.07
Hypertension 1.24 (0.85, 1.80) 0.26
MI 0.79 (0.39, 1.62) 0.52
Solid tumour 8.15 (4.53, 14.6) <0.001
Mild liver disease 2.48 (0.88, 7.01) 0.09
PVD 1.18 (0.58, 2.41) 0.64
Peptic ulcer 2.82 (1.00, 7.93) 0.05
Renal disease 0.48 (0.24, 0.96) 0.04
Rheumatic disease 0.63 (0.22, 1.81) 0.39
Missing data 1.45 (0.82, 2.54) 0.20
GFR > 60 1 0.92
GFR 45 - < 60 0.95 (0.61, 1.48)
Table 6 This table shows logistic regression analysis at
30 days with AKI defined by absolute change as separate
groups (Continued)
GFR 30 - < 45 0.92 (0.53, 1.58)
GFR < 30 1.24 (0.53, 2.91)
Time measurement (†) 0.84 (0.80, 0.89) <0.001
8 No AKI 1 <0.001
-AKI 1 9.55 (5.89, 15.5)
-AKI 1a 3.63 (2.24, 5.87)
-AKI 2 38.9 (22.8, 66.3)
-AKI 3 163 (81.6, 327)
-AKI 3a 27.0 (3.00, 243)
Female sex 0.67 (0.48, 0.94) 0.02
Age (*) Linear term 0.54 (0.20, 1.48) <0.001
Squared term 1.10 (1.03, 1.18)
Charlson ≤0 1 <0.001
1-10 2.92 (1.73, 4.93)
11+ 5.95 (3.68, 9.64)
No info 1.97 (1.06, 3.66)
GFR > 60 1 0.45
GFR 45 - < 60 0.80 (0.52, 1.23)
GFR 30 - < 45 0.70 (0.41, 1.18)
GFR < 30 0.69 (0.31, 0.56)
Time measurement (†) 0.84 (0.80, 0.88) <0.001
(*) Odds Ratio reported for a 10-year increase in age.
(†) Time from baseline to AKI creatinine measurement (months).
This table shows the logistic regression analysis for the like-hood of dying in the first
30 days following an acute elevation in serum creatinine. Model 6 adjusts for age
and gender, model 7 also adjusts for individual co-morbidity and time between
incident creatinine and baseline creatinine, model 8 replaces co-morbidity with a
Charlson score to measure the effect of cumulative co-morbidity burden and time
between incident creatinine and baseline creatinine.
Chronic Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD),
Myocardial Infarction (MI), Peripheral Vascular Disease (PVD), Chronic Kidney
Disease (CKD).
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the odds were over 200 times greater for AKI 3 patients,
however the Confidence Intervals (CI) were large and
the numbers in AKI 3a and AKI 3 (Table 7).
Discussion
This study is the first to describe the survival outcome
associated with acute elevations in SCr occurring entirely
in primary care without subsequent non-elective admis-
sion to hospital. However there have been a small number
of in-hospital studies that have compared community ac-
quired AKI ( CA-AKI) with Hospital acquired (HA-AKI)
which have found that number of CA-AKI was higher
than HA- AKI on a ratio 3:1 [24-26]. The incidence of
acute elevations in SCr fulfilling AKIN criteria in our
study population was estimated to be 14,132 per million
adult population per year (pmap/yr) which is similar in
Figure 4 Kaplan-Meier Survival by AKIN Criteria, including AKI
defined by absolute change alone, all patients (n = 61,432). This
figure shows the survival criteria up to 24 months this is split into
two categories to show the effect on those defined using and an
absolute change only compared against those defined using a
relative change.
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same population, which estimated an in-hospital incidence
of 15,352 pmap/yr [20]. This implies that in total 5% of
the adult population of East Kent have experienced an
acute elevation in SCr fulfilling AKIN criteria during the
study time period. Although the majority of the acute
elevations in SCr in managed in primary care were skewed
to AKI 1 than in other in-hospital studies [20].
We have been careful to describe these acute elevations
in SCr as fulfilling AKIN creatinine criteria rather than
defined as AKI because it was not possible to fulfil the
time constraints for either the AKIN or RIFLE [10] defini-
tions of AKI because blood tests in the community are
seldom repeated within 48 hours. Instead we used the
methodology described by La France and Miller21 which
extends the time to reference creatinine to 12 months.
Whilst this may increase the incidence of acute elevations
in SCr corresponding to AKIN stage 1, relative to time to
baseline creatinine, the evidence suggests that such small
rises have a significant adverse effect on outcome inTable 7 Number of incidences of AKI for each Stage of CKD
Stage CKD (MDRD)
Stage 1 Stage
AKI Stage with absolutes No AKI 45377 86
AKI 1 939





This table shows the number of incidences at each stage AKI per stage of CKD, usin
alone. ** Defined using an absolute change of > 353.6 mmols/l with an acute increahospital inpatients [7]. However, in model 7 and 8 we ad-
justed the analysis for time to baseline in months. Despite
the fact that this showed each months increase had a very
small significant effect on reducing the risk of mortality,
this is unlikely to have large impact on outcome (Table 7).
Our data supports the opinion that the risk of mortality
is directly associated with acute elevation in serum creatin-
ine occurring and managed entirely in primary care. This
risk is still apparent even in small rises in serum creatinine.
Although this may be associated with pre-existing higher
levels of mortality compared with the reference group the
risk of mortality in the first 30 days is significant. These
results are comparable to the in-hospital study [20] which
also reports and increasing risk of death by stage in 30 days.
Whilst the community study had fewer patients with AKI 2
and AKI 3, this was offset by larger numbers of AKI 1
giving a similar overall incidence. Although there are no
comparable studies in primary care, other studies in Wales
and in the USA [24-26] comparing CA-AKI and HA-AKI
have also found an association between AKI and survival in
the first 30 days, and that the risk of death increases with
stage AKI. These similarities suggest that acute elevations
in serum creatinine occurring and managed in the commu-
nity may represent a health risk and merit further investiga-
tion and better understanding. It will be important to
ascertain why the tests were requested, whether these acute
SCr elevations in primary care are actually recognised and
prompt further action, or whether they go unrecognised by
the healthcare system. This is something we have hypothe-
sised may contribute to the development of CKD in the
general population [27].
Furthermore this study showed an excess of AKI 1
and 3 in people with advanced CKD (Stage 4&5). The
majority of this was defined by an absolute change in
serum creatinine rather than a relative change (Table 5).
When analysed separately those defined by an absolute
change had less of a risk that those defined by a relative
change. Although AKI 1a had a smaller risk than AKI 1
it was still significant when compared to the reference
group. While the patient numbers are small, the survivalTotal
3a Stage 3b Stage 4 Stage 5
12 2736 552 23 57300
90 81 27 1 1138
98 568 339 18 2660
42 18 7 0 232
8 7 1 0 68
0 0 3 31 34
50 3410 929 73 61432
g the AKIN Criteria. * Defined using an absolute change of >26.5mmols/l
se of at least 0.5 mg/dl (44μmols/l) alone.
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those in AKI 3. Since all those grouped in 3a had stage 4
or 5 CKD it may be possible that this group does not
represent an acute episode and suggests that the AKIN
criteria in advanced CKD may be overly sensitive. This
has been shown in other studies [28].
This study has limitations, firstly patients were recruited
from a single county in the United Kingdom. Whilst the
study recruited large numbers of patients the population
of East Kent, it is not entirely representative of the United
Kingdom demographic therefore the population studied is
older with fewer ethnic minorities than the national aver-
age [29]. However, it is not unreasonable to assume that
primary care practice in Kent is similar to that in the rest
of the UK. Never the less care should be taken when relat-
ing the findings to an international setting particularly
bearing in mind that provision of primary care services
differs considerably, particularly across Europe.
Secondly, as this was an observational study and patients
could only be included if they had had a SCr test, therefore
the study population may represent a more co-morbid
population that the general population. Also co-morbidity
data was taken from hospital records and only patients who
had had hospital admissions prior to the study period
would have recorded co-morbidity. Although Charlson
Scores based on administrative data may underestimate the
prevalence of co-morbid disease NHS administrative data
accuracy has been shown to be improving in recent years.
Systematic review suggests that current levels of reported
accuracy are sufficiently robust to support their use for
research [22,30]. Although it is probable that some patients
with significant co-morbidity had none recorded (either
because of no previous admission or an incomplete record)
it is worth noting that 47,716 of 61,432 patients included in
the study had recorded co-morbidity. Furthermore the ab-
sence of a co-morbidity record was included in the multi-
variate model allowing the model to account for missing
variables, particularly as they are not missing at random.
Finally, the study only examined the hospital records
of the local NHS hospital Trust, it is possible that pa-
tients could have been admitted to other surrounding
hospitals or non NHS providers. However, in reality very
few patients are admitted to non NHS providers as non-
elective patients in the UK. The recruitment area was a
peninsula (East Kent, UK) the vast majority of acute ad-
missions in the area are to the single provider examined.
This study group was a carefully selected cohort of pa-
tients with no acute hospital admissions in the eighteen
months follow up period, thus removing the potential
confounding of subsequent hospital admission. However,
this may mean that we have underestimated the impact
of acute elevations of SCr in primary care. It is also likely
that patients with higher acute SCr elevations were
recognised and admitted to hospital.Conclusion
In conclusion, this study suggests patients who develop
acute SCr elevations in primary care and are not subse-
quently admitted to hospital have a significantly increased
mortality compared to those whose SCr is stable. The
increased mortality appears to be temporally associated
with the acute SCr elevation, i.e. within 30 days, suggest-
ing a direct association between the event and adverse
outcome. This association persists even after multiple
adjustments for potential confounders. Further studies
are required to examine the potential causal association
between these events in primary care and poor outcome.
Clearly if there is a causal relationship this would be an
important area in which to intervene.
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